Login to Your Account

Other News To Note

Tuesday, April 17, 2012
• Nascent Biologics Inc., of Somerset, N.J., inked a deal for Catalent Pharma Solutions, of San Diego, to engineer a cell line expressing Nascent's Pritumumab antibody and subsequently produce purified monoclonal antibodies to support Nascent's Phase I/II trials in brain cancers such as astrocytomas and glioblastomas.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription